News

Li discusses microneedling innovations, global techniques, safety, and future trends in dermatology, including integration with RF and PRP.

An analysis of 70 studies shows that MMS reduces local recurrence to 5.0% compared to 17.7% for WLE in anogenital SCC cases.

Wendy Smith Begolka, MBS, and Renata Block, MMS, PA-C discuss the NEA's expanded eczema visual guide and upcoming Chicago event to support diverse patient communities.

A majority of patients noticed improvement in hyperpigmentation spots, skin texture and evenness after 12 weeks of use.

EltaMD’s Derm Difference campaign honors dermatologists’ expertise in skin health, cancer prevention, and confidence-boosting care.

By leveraging the innovative biomarker panels, clinicians can now offer more personalized and effective treatment options for psoriasis and AD.

The COVID-19 pandemic reshaped dermatology through telehealth, social media, and increased cosmetic procedures. Challenges and opportunities persist as practices adapt.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Christopher Bunick, MD, PhD, reviewed the evolving role of antibiotics, emphasizing antibiotic stewardship, the gut-skin connection, and the importance of narrow-spectrum antibiotics at AAD 2025.

Wendy Smith Begolka, MBS, and Renata Block, MMS, PA-C, discuss redefining eczema flares to align clinical and patient perspectives.

The agency shared details of additional voluntary recalls and its plans to release full results of its independent testing in the coming months.

It can help keep your patients coming back. Everyday promotional financing with the CareCredit health, wellness and beauty credit card can help make you a top choice. What can this do for your practice? Simplify the process From faster payments and enhanced satisfaction to support for practices and their teams, CareCredit can help simplify care with no cost for your practice to enroll. Help boost patients' confidence in their care With more than 35 years of experience, CareCredit is a trustworthy and transparent way for patients to pay for your full recommendation and fit care in their budget. Help improve patient loyalty Once patients are approved for the CareCredit credit card, they can use it to pay upfront and come back again and again for future care.

Nearly all patients in a new study saw an improved appearance in their forehead up to 12 months after treatment.

This week, we feature top articles from our sister publications on updates in surgical management, diabetes control, and more.

Renata Block, MMS, PA-C, speaks with Wendy Smith Begolka, MBS, of the National Eczema Association about NEA’s strategic efforts in community outreach, health care provider engagement, and patient education.

Bissonnette shared highlights and insights on the icotrokinra data presented at the AAD Annual Meeting.

Compared to placebo, there was a 70% reduction in IgE levels in children ages 0.5 to 6 after 16 weeks of therapy.

Ruxolitinib cream showlasting safety and efficacy in children with moderate to severe atopic dermatitis.

This review of the latest dermatologic studies includes insights into erectile dysfunction in dermatology and venereology, diet and psoriasis information on TikTok, and more.

Catch up on coverage from the final day of the 2025 American Academy of Dermatology Annual Meeting held in Orlando, Florida.

Test your knowledge of key words and terms associated with dermatology meeting news from the previous week.

Christopher Bunick, MD, PhD, discussed how to interpret recent benzene research as clinicians await regulatory guidance for benzoyl peroxide.

New results from Alumis show a positive clinical response and safety profile after 52 weeks of treatment for patients with plaque psoriasis.

Gold highlighted the growing role of energy-based devices in acne treatment during his AAD session.

The study found half of the patients receiving once-monthly lebrikizumab achieved complete skin clearance at 3 years, with 87% maintaining near-clearance.

Anabela Cardoso, MD, discussed lebrikizumab’s efficacy in improving itch, skin pain, sleep disturbance, and long-term management in atopic dermatitis.

Explore the top headlines of the week including insights on the environmental impact of conferences, new clinical data, and the shift towards more natural-looking results.

Efficacy, safety, and pharmacokinetic data support the use of vilobelimab in treating pyoderma gangrenosum and hidradenitis suppurativa.

Johnson & Johnson’s JNJ-2113 showed promise for PsO, achieving high skin clearance with a strong safety profile.

Catch up on coverage from the fourth day of the 2025 American Academy of Dermatology Annual Meeting held in Orlando, Florida.